Welcome back: Outsourcing in Clinical Trials New England 20131-2 October 2013, Boston, MA
At Arena International we go to extreme lengths to get to know our audience and cater to their specific needs and wishes. The OCT team lives and breathes conferences in the biotech and pharma space, allowing us to create truly innovative and inspired events.
We are proud to invite you to Arena International’s 5th annual Outsourcing in Clinical Trials New England conference – the flagship event of our entire series –and to actively get involved in what promises to be another exceptional event.
In October 2013, OCT New England will once again prove industry leadership in providing cutting-edge solutions and a phenomenal speaker faculty.
Building on last year’s roaring success, this year’s agenda has been compiled with the help of OCT New England Advisory Board, bringing unprecedented value to CROs, biotechnology and pharmaceutical companies alike.
Our agenda will present a varied yet balanced range of topics to ensure an in-depth but holistic overview of Outsourcing in Clinical Trials.
We are excited to announce that the Venue for OCT New England will be the Westin Boston Waterfront.
Thanks to everyone who attended the OCT Southeast conference in Cary, North Carolina on 7-8th May, 2013. We now have some photos of the event uploaded. Check back regularly for an updated version.
The Outsourcing Clinical Trial series is growing every year. View the full list of upcoming events to make sure you don’t miss any news.
We are proud to boast the following feedback from attendees at our Outsourcing Series:
Our established and reputable clinical portfolio hosts a range of strategic, broad-reaching, technical and niche events; all of which are researched with and presented by highly-regarded figureheads within the industry and supported by numerous key industry providers.
Switzerland-based Celgene International's Phase II trial of oral small-molecule inhibitor of phosphodiesterase 4 (PDE4), Apremilast, has demonstrated statistical significance for primary and secondary endpoints in patients with Behcet's disease (BD).
US-based Omeros has received regulatory approval to commence a Phase I clinical trial of OMS721, the firm's lead human monoclonal antibody from its mannan-binding lectin-associated serine protease-2 (MASP-2) programme.
Cancer Research UK's commercial arm, Cancer Research Technology (CRT), has entered into two partnership agreements with the University of Manchester and British biopharmaceutical firm AstraZeneca to develop new cancer drugs.
Global biopharmaceutical company UCB has announced positive results from its Phase IIb open-label extension study of epratuzumab, which is being developed to treat systemic lupus erythematosus (SLE) or lupus.
The Chinese Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE) has signed a strategic co-operation contract with blue inspection body, the German Good Manufacturing Practices (GMP) third party auditor, to maintain drug …
Biotechnology company Amgen has reported that its Phase III TRINOVA-1 trial of trebananib plus paclitaxel has met the primary endpoint of progression-free survival (PFS) in the treatment of patients suffering from recurrent ovarian cancer.
Biopharmaceutical company Trigemina has started patient enrolment in Phase II trial of TI-001 (intranasal oxytocin) for the treatment of chronic migraine.